Dynamic alterations of gene expression of nicotinic acetylcholine receptor α7, α4 and β2 subunits in an acute MPTP-lesioned mouse model

Neuroscience Letters

Volumn 494, Issue 3, 2011, Pages 232-236

  Hu, Jun ^a   Zhu, Chenlei ^a   Liu, Yuan ^a   Wang, Fang ^b   Huang, Zuhu ^a   Fan, Weimin ^a   Wu, Jie ^c  

^a THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^b NANJING MEDICAL UNIVERSITY   (China)

^c BARROW NEUROLOGICAL INSTITUTE   (United States)

Author keywords

Mouse model; MPTP; MRNA; Nicotinic acetylcholine receptors; Parkinson's disease

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; MESSENGER RNA; NICOTINIC ACETYLCHOLINE RECEPTOR ALPHA7; NICOTINIC RECEPTOR; NICOTINIC RECEPTOR ALPHA4BETA2; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; BRAIN TISSUE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC NERVE CELL; GENE EXPRESSION; HIPPOCAMPUS; INTOXICATION; MALE; MOTOR ACTIVITY; MOUSE; NERVE DEGENERATION; NONHUMAN; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SUBSTANTIA NIGRA;

ANIMALS; BRAIN; DISEASE MODELS, ANIMAL; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; MICE; PARKINSONIAN DISORDERS; RECEPTORS, NICOTINIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 79954415405     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neulet.2011.03.022     Document Type: Article

References (20)

1. Arai N., Misugi K., Goshima Y., Misu Y. Evaluation of a 1-methyl-4-phenyl-1 2,3,6-tetrahydropyridine (MPTP)-treated C57 black mouse model for parkinsonism. Brain Res. 1990, 515:57-63.
2. Bencherif M. Neuronal nicotinic receptors as novel targets for inflammation and neuroprotection: mechanistic considerations and clinical relevance. Acta Pharmacol. Sin. 2009, 30:702-714.
3. Burghaus L., Schutz U., Krempel U., Lindstrom J., Schroder H. Loss of nicotinic acetylcholine receptor subunits alpha4 and alpha7 in the cerebral cortex of Parkinson patients. Parkinsonism Relat. Disord. 2003, 9:243-246.
4. Camicioli R., Moore M.M., Kinney A., Corbridge E., Glassberg K., Kaye J.A. Parkinson's disease is associated with hippocampal atrophy. Mov. Disord. 2003, 18:784-790.
5. de Jonge W.J., Ulloa L. The alpha7 nicotinic acetylcholine receptor as a pharmacological target for inflammation. Br. J. Pharmacol. 2007, 151:915-929.
6. Fan Y., Kong H., Shi X., Sun X., Ding J., Wu J., Hu G. Hypersensitivity of aquaporin 4-deficient mice to 1-methyl-4-phenyl-1 2,3,6-tetrahydropyrindine and astrocytic modulation. Neurobiol. Aging 2008, 29:1226-1236.
7. Farina C., Aloisi F., Meinl E. Astrocytes are active players in cerebral innate immunity. Trends Immunol. 2007, 28:138-145.
8. Furuya T., Hayakawa H., Yamada M., Yoshimi K., Hisahara S., Miura M., Mizuno Y., Mochizuki H. Caspase-11 mediates inflammatory dopaminergic cell death in the 1-methyl-4-phenyl-1 2,3,6-tetrahydropyridine mouse model of Parkinson's disease. J. Neurosci. 2004, 24:1865-1872.
9. Guan Z.Z., Nordberg A., Mousavi M., Rinne J.O., Hellstrom-Lindahl E. Selective changes in the levels of nicotinic acetylcholine receptor protein and of corresponding mRNA species in the brains of patients with Parkinson's disease. Brain Res. 2002, 956:358-366.
10. Hirsch E.C., Hunot S. Neuroinflammation in Parkinson's disease: a target for neuroprotection?. Lancet Neurol. 2009, 8:382-397.
11. Hosur V., Leppanen S., Abutaha A., Loring R.H. Gene regulation of alpha4beta2 nicotinic receptors: microarray analysis of nicotine-induced receptor up-regulation and anti-inflammatory effects. J. Neurochem. 2009, 111:848-858.
12. Jakowec M.W., Petzinger G.M. 1-Methyl-4-phenyl-1 2,3,6-tetrahydropyridine-lesioned model of Parkinson's disease, with emphasis on mice and nonhuman primates. Comp. Med. 2004, 54:497-513.
13. Kuroiwa H., Yokoyama H., Kimoto H., Kato H., Araki T. Biochemical alterations of the striatum in an MPTP-treated mouse model of Parkinson's disease. Metab. Brain Dis. 2010, 25:177-183.
14. Lees A.J., Hardy J., Revesz T. Parkinson's disease. Lancet 2009, 373:2055-2066.
15. Liberatore G.T., Jackson-Lewis V., Vukosavic S., Mandir A.S., Vila M., McAuliffe W.G., Dawson V.L., Dawson T.M., Przedborski S. Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease. Nat. Med. 1999, 5:1403-1409.
16. Park H.J., Lee P.H., Ahn Y.W., Choi Y.J., Lee G., Lee D.Y., Chung E.S., Jin B.K. Neuroprotective effect of nicotine on dopaminergic neurons by anti-inflammatory action. Eur. J. Neurosci. 2007, 26:79-89.
17. Quik M., Bordia T., O'Leary K. Nicotinic receptors as CNS targets for Parkinson's disease. Biochem. Pharmacol. 2007, 74:1224-1234.
18. Quik M., Huang L.Z., Parameswaran N., Bordia T., Campos C., Perez X.A. Multiple roles for nicotine in Parkinson's disease. Biochem. Pharmacol. 2009, 78:677-685.
19. Sedelis M., Schwarting R.K., Huston J.P. Behavioral phenotyping of the MPTP mouse model of Parkinson's disease. Behav. Brain Res. 2001, 125:109-125.
20. Yasuda Y., Shimoda T., Uno K., Tateishi N., Furuya S., Yagi K., Suzuki K., Fujita S. The effects of MPTP on the activation of microglia/astrocytes and cytokine/chemokine levels in different mice strains. J. Neuroimmunol. 2008, 204:43-51.